Correlation Between Programmed Cell Death Ligand1 (PD-L1) Expression and Clinical Parameters in Colorectal Carcinoma.
AbstractObjectives: Programmed Cell Death Ligand1 (PD-L1) tissue expression in CRC (colorectal cancer) displays conflicting results among various studies. We aimed to identify the rate of PD-L1 positivity in colorectal carcinoma, and it's immune infiltrating cells, their relationship with clinicopathologic parameters of patients, and to correlate the results with other studies.
Methods: PD-L1 antibody retrospectively analyzed immunohistochemically in tissue microarray blocks of 99 specimens with colonic and rectal carcinomas operated between January 2015 to December 2017. A comparison performed between PD-L1 expression in tumor cells (TCs) as well as tumor-infiltrating immune cells (TIICs) for age, sex, histological differentiation, the primary tumor location, number of involved lymph nodes, angiolymphatic invasion, and TNM stage.
Results: Of the 99 patients, the median age was 54.5 (range: 18 to 83) years. Fourteen samples were PD-L1 positive in TCs, increased to 32% in TIICs. A significant expression of PD-L1in TCs was correlated with medullary histology (p= 0.03), number of the involved lymph nodes (p= 0.02), distant metastasis (p= 0.001), and TNM stage (p= 0.0001). The PD-L1 status in TIICs was again connected with adverse clinical and pathological parameters.
Conclusions: The expression of PD-L1 in TCs and TIICs is associated significantly with advanced cancer or lymphatic invasion in patients who underwent surgery after a diagnosis of CRC. The research designates the significance of estimation of TCs and TIICs in correlation to clinicopathologic characteristics of patients a finding that could produce a piece of evidence for precise electing immunotherapy.
Keywords: Programmed cell death ligand1, colorectal carcinoma, Tissue microarray study, Immunohistochemistry.
1. Bray F. Ferlay j, Soerjomataram I, Siegel RL, Torre LA and jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer j Clin. 2018;68:394-424.
2. Schott DS, Pizon M, Pachmann U, Pachmann K. Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors. Oncotarget. 2017;8(42):72755.
3. Valentini AM, Di Pinto F, Cariola F, Guerra V, Giannelli G, Caruso ML, et al. PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. Oncotarget. 2018;9(9):8584.
4. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. New England Journal of Medicine. 2012;366(26):2443-54.
5. Bertucci F, Finetti P, Mamessier E, Pantaleo MA, Astolfi A, Ostrowski J, et al. PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology. 2015;4(5):e1002729.
6. Zhou C, Tang J, Sun H, Zheng X, Li Z, Sun T, et al. PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. Oncotarget. 2017;8(35):58457.
7. Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiology and Prevention Biomarkers. 2014;23(12):2965-70.
8. Li Y, Liang L, Dai W, Cai G, Xu Y, Li X, et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Molecular cancer. 2016;15(1):55.
9. Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PloS one. 2013;8(6):e65821.
10. Amin MB, Edge SB. AJCC cancer staging manual: springer; 2017.
11. Shaban ZM, Al-Aubaidy SR, Hameedi AD. Idh1 mutation in gliomas in baghdad by immunohistochemical study. International Journal of Genetics and Genomics. 2018;6(1):1-7.
12. Inaguma S, Lasota J, Wang Z, Felisiak-Golabek A, Ikeda H, Miettinen M. Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Modern Pathology. 2017;30(2):278-85.
13. Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Modern pathology. 2016;29(9):1104-12.
14. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. European journal of cancer. 2013;49(9):2233-42.
15. Lee KS, Kim BH, Oh HK, Kim DW, Kang SB, Kim H, et al. Programmed cell death ligand‐1 protein expression and CD 274/PD‐L1 gene amplification in colorectal cancer: Implications for prognosis. Cancer science. 2018;109(9):2957-69.
16. Masugi Y, Nishihara R, Yang J, Mima K, Da Silva A, Shi Y, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2017;66(8):1463-73.
17. Zhu H, Qin H, Huang Z, Li S, Zhu X, He J, et al. Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma. International journal of clinical and experimental pathology. 2015;8(8):9351-9. PubMed PMID: 26464688. Pubmed Central PMCID: PMC4583920. Epub 2015/10/16. eng.
18. Elfishawy M, Abd ESA, Hegazy A, El-Yasergy DF. Immunohistochemical Expression of Programmed Death Ligand-1 (PDL-1) in Colorectal carcinoma and Its Correlation with Stromal Tumor Infiltrating Lymphocytes. Asian Pacific journal of cancer prevention : APJCP. 2020 Jan 1;21(1):225-32. PubMed PMID: 31983188. Pubmed Central PMCID: PMC7294013. Epub 2020/01/28. eng.
19. Shan T, Chen S, Wu T, Yang Y, Li S, Chen X. PD-L1 expression in colon cancer and its relationship with clinical prognosis. International journal of clinical and experimental pathology. 2019;12(5):1764-9. PubMed PMID: 31933995. Pubmed Central PMCID: PMC6947132. Epub 2020/01/15. eng.
20. Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1). Proceedings of the National Academy of Sciences. 2018;115(43):E10119-E26.
21. Lee LH, Cavalcanti MS, Segal NH, Hechtman JF, Weiser MR, Smith JJ, et al. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Modern Pathology. 2016;29(11):1433-42.
22. Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression. The Journal of clinical investigation. 2018;128(2):805-15.
23. Wang L, Ren F, Wang Q, Baldridge LA, Monn MF, Fisher KW, et al. Significance of programmed death ligand 1 (PD-L1) immunohistochemical expression in colorectal cancer. Molecular diagnosis & therapy. 2016;20(2):175-81.
24. Park J-J, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood. 2010;116(8):1291-8.
25. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007 Jul;27(1):111-22. PubMed PMID: 17629517. Pubmed Central PMCID: PMC2707944. Epub 2007/07/17. eng.
26. Pflughoeft KJ, Versalovic J. Human Microbiome in Health and Disease. Annual Review of Pathology: Mechanisms of Disease. 2012;7(1):99-122. PubMed PMID: 21910623.